Pharmacological treatments for methamphetamine addiction: current status and future directions
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Methamphetamine (MA) abuse remains a global health challenge despite intense research interest in the development of pharmacological treatments. This review provides a summary of clinical trials and human studies on the pharmacotherapy of methamphetamine use disorder (MUD). Areas covered: We summarize published clinical trials that tested candidate medications for MUD and also conducted PubMed and Google Scholar searches to identify recently completed clinical trials using the keywords 'methamphetamine' 'addiction' 'pharmacotherapy' and 'clinical trial.' To determine the status of ongoing clinical trials targeting MUD, we also searched the ClinicalTrials.gov online database. We conclude this review with a discussion of current research gaps and future directions. Expert commentary: Clinical trials examining the potential for pharmacotherapies of MUD have largely been negative. Future studies need to address several limitations to reduce the possibility of Type II errors: small sample sizes, high dropout rates or multiple comorbidities. Additionally, new treatment targets, such as MA-induced disruptions in cognition and in the neuroimmune system, merit trials with agents that selectively modulate these processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurobiology of addiction: a neurocircuitry analysis
Koob, G. F., & Volkow, N. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00104-8 · Cited by 3,698 · cited 2×
“Glutamate, the main excitatory neurotransmitter in the brain, is one of the primary mediators driving sensitization and craving in response to stimulant drugs [35], and in preclinical models, glutamate plays an essential role in drug and cue-induced reinstatement [36] suggesting a role for glutamate in relapse to drug…”
BackgroundA Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders
Dutra, L., Stathopoulou, G., Basden, S. L., Leyro, T. M., Powers, M. B., & Otto, M. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111851 · Cited by 1,287
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Conway, K. P., Compton, W., Stinson, F. S., & Grant, B. F. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0211 · Cited by 934 · cited 1×
“National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) data has shown that among individuals who use MA, the lifetime prevalence of mood and anxiety disorders was 51% and 39%, respectively [29].”
BackgroundScofield, M. D., Heinsbroek, J. A., Gipson, C. D., Kupchik, Y. M., Spencer, S., Smith, A. C. W., Roberts-Wolfe, D., & Kalivas, P. W. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012484 · Cited by 598 · cited 1×
“In addition, thorough its central role in drug-induced neuronal plasticity [37], alterations in glutamatergic signaling may explain other phenomena such as protracted abstinence [36].”
BackgroundClinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., & Frye, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.015 · Cited by 463
The dark side of emotion: the addiction perspective
Koob, G. F. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.044 · Cited by 433 · cited 1×
“Finally, Ach likely participates in mediating the cognitive-enhancing effects of MA, including sustained attention [38], and both acute exposure to MA, and abstinence from MA use, activate CRF and stress-hormone pathways [39].”
BackgroundMethamphetamine use: A comprehensive review of molecular, preclinical and clinical findings
Panenka, W. J., Procyshyn, R. M., Lecomte, T., MacEwan, G. W., Flynn, S. W., Honer, W. G., & Barr, A. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.016 · Cited by 432 · cited 3×
“ventral tegmental area DA projection neurons and their primary targets, the nucleus accumbens (NAc) and prefrontal cortex (PFC) [9].”
BackgroundGlial and Neuroimmune Mechanisms as Critical Modulators of Drug Use and Abuse
Lacagnina, M. J., Rivera, P. D., & Bilbo, S. D. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.121 · Cited by 271 · cited 1×
“induced and subjective responses to MA were reduced in those subjects who received naltrexone over placebo [67].”
BackgroundPsychostimulant abuse and neuroinflammation: emerging evidence of their interconnection.
Clark, K. H., Wiley, C. A., & Bradberry, C. W. (2013) · Neurotoxicity Research · doi:10.1007/s12640-012-9334-7 · Cited by 194
Mirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175 · cited 1×
“02), and also reduced sexual risk behaviors [12].”
BackgroundPsychiatric comorbidity in methamphetamine dependence
Salo, R., Flower, K., Kielstein, A., Leamon, M. H., Nordahl, T. E., & Galloway, G. P. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2010.09.014 · Cited by 151 · cited 1×
“In another survey of a clinical sample (n = 189) with a MUD, 57% had lifetime dependence on other substances (alcohol 33%, cocaine 27%, cannabis 15%, opioids 12%) [30].”
BackgroundStimulant-induced dopamine increases are markedly blunted in active cocaine abusers
Volkow, N. D., Tomasi, D., Wang, G.-J., Logan, J., Alexoff, D. L., Jayne, M., Fowler, J. S., Wong, C., Yin, P., & Du, C. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.58 · Cited by 134 · cited 1×
“However, a recent critical review of neuropsychological and neuroimaging data questioned the clinical significance of previously shown changes in human cognition [54], while an even more recent comprehensive review of data from animal studies, twin studies, neuroimaging, cross sectional and longitudinal studies conclu…”
BackgroundSimon, S. L., Dean, A. C., Cordova, X., Monterosso, J. R., & London, E. D. (2010) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2010.71.335 · Cited by 117 · cited 1×
“Although the exact mechanisms remain elusive, some authors have proposed an inhibitory effect of oxytocin in the reward circuit, particularly in the nucleus accumbens and subthalamic nucleus projections [84].”
BackgroundAnderson, A. L., Li, S.-H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., Campbell, J., Dickerson, D. L., Galloway, G. P., Haning, W., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.036 · Cited by 70
Cited by
Bupropion and naltrexone in methamphetamine use disorder
Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2020214 · Cited by 281
Jones, C. M., Houry, D., Han, B., Baldwin, G., Vivolo‐Kantor, A., & Compton, W. M. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14688 · Cited by 202
Hamel, C., Corace, K., Hersi, M., Rice, D., Willows, M., Macpherson, P., Sproule, B., Flores-Aranda, J., Garber, G., Esmaeilisaraji, L., et al. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01499-z · Cited by 17
“, naltrexone [84, 85]), antidepressants [6, 31, 86]”
Li, Y., Re, G.-F., Zhao, Y., Kong, D., Mao, J.-H., Wang, K.-H., & Kuang, Y.-Q. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-450 · Cited by 6
Metadata
- Authors
- Ballester, J., Valentine, G., & Sofuoglu, M.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2016-12-20
- Volume
- 10
- Issue
- 3
- Pages
- 1-10
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2560639606
- Cited by
- 89
- References
- 15
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.